G
Greenlight Biosciences
Biotech & Life Sciences · Medford, United States · Founded 2008
GreenLight Biosciences employs the Unconstrained Metabolism(R) technology platform to produce sustainable chemicals and fuels MoreLess
Greenlight Biosciences was founded in 2008 by Andrey Zarur and Marta Ortega-Valle with a mission to harness the power of RNA to address critical challenges in agriculture and human health. The company set out to develop innovative RNA-based solutions that could transform the way we approach pest control and crop management, aiming for a more sustainable and equitable food system.
In its journey, Greenlight Biosciences achieved a significant milestone in August 2021 by going public through a $1.2 billion SPAC merger with Environmental Impact Acquisition Corp. This move provided the company with the necessary capital to expand its research and development efforts and bring its groundbreaking products to a broader market.
Continuing its trajectory of growth and innovation, Greenlight Biosciences announced in May 2023 that it would be acquired by Fall Line Capital in a go-private transaction. This acquisition marked a new chapter for the company, allowing it to focus on long-term strategic goals without the pressures of public market fluctuations.
Throughout its history, Greenlight Biosciences has remained committed to its founding vision, leveraging RNA technology to create solutions that not only improve agricultural productivity but also promote environmental sustainability. The company's journey reflects a steadfast dedication to innovation and impact, positioning it as a leader in the field of biosciences.
Company overview
Greenlight Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2008
- Headquarters
- Medford, United States
- Employees
- 179
- Open positions
- 1
- Dealroom signal
- 65.3
Valuation & funding
Greenlight Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Mar 2025 | $25M | — | Just Climate | ↗ |
| DEBTDebt | Feb 2025 | $39M | — | European Investment Bank | ↗ |
| ACQUISITIONOther financing | May 2023 | $46M | $46M | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Aug 2022 | $109M | — | Undisclosed | ↗ |
| SPAC PRIVATE PLACEMENTOther financing | Aug 2021 | $105M | $1.2B | BNP Paribas · Morningside · Hudson Bay Capital Management · Xeraya Capital | ↗ |
| SPAC IPOOther financing | Aug 2021 | Environmental Impact Acquisition Corp | ↗ | ||
| LATE VCOther financing | May 2020 | Xeraya Capital · Baird Capital · Flu Lab | ↗ | ||
| LATE VCOther financing | Jan 2019 | Robert W. Baird & Co. · Prelude Ventures · S2G Investments | — | ||
| SERIES DOther financing | Sep 2017 | S2G Investments · Syngenta Ventures · Lewis & Clark Ventures · Kodiak Venture Partners | — | ||
| SERIES COther financing | Jul 2015 | Khosla Ventures · Syngenta Ventures | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $6.4M | 0% | −$154M | -2408.6% |
| 2025 | $6.4M | 0% | −$154M | -2408.6% |
| 2024 | $6.4M | 0% | −$154M | -2408.6% |
| 2023 | $6.4M | 0% | −$154M | -2408.6% |
| 2022 | $6.4M | 0% | −$154M | -2408.6% |
| 2021 | $6.4M | +563.6% | −$104M | -1630.9% |
| 2020 | $962K | — | −$50M | -5246.3% |
Growth signals
Greenlight Biosciences website traffic
Latest recorded traffic for Greenlight Biosciences is 3.3K monthly website visits, up 37.5% over the last three months. Greenlight Biosciences's team declined 34.4% over the past year.
Hiring
Open positions at Greenlight Biosciences
Current openings linked to this company in Dealroom.
Comparisons
Greenlight Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Greenlight Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Greenlight Biosciences has talent and traffic
team presence
In the news
Latest news about Greenlight Biosciences
Recent press, funding announcements, and product moves mentioning Greenlight Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Greenlight Biosciences
An AI-synthesized read of the highest-engagement posts about Greenlight Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Greenlight Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.